The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Hepatitis C infection in Egypt: prevalence, impact and management strategies
Open accessAbstract
Hepatitis C virus (HCV) infection is a major public health burden in Egypt, where it bears the highest prevalence rate in the world. Estimates for prevalence are based upon data reported from the 2008 and 2015 Egypt Demographic Health Surveys. In this review, we demonstrate the prevalence results of both surveys and analyze the difference in the results. The overall HCV prevalence is estimated to be declining. However, the clinical impact of chronic HCV infection is expected to grow considerably. A mathematical model shows that by increasing the rate of treatment, the expected number of patients will decline significantly in 2030. The current and expected future burden of chronic HCV infection to the Egyptian economy, including direct and indirect costs due to disability and loss of lives, has been estimated and discussed in this review. The economic burden will continue to grow, but a model shows that the introduction of highly effective therapies will result in a significant reduction in the cumulative total economic burden of HCV by 2030. In recognition of the HCV tremendous health and economic burden, the Egyptian government established the National Committee for Control of Viral Hepatitis to implement an integrated nationwide strategy to provide patient care and ensure global treatment access. This review illustrates the epidemiological and disease burden aspects of HCV in Egypt in addition to introducing the national plan and program for managing HCV, which has been successful so far in treating a large number of patients, with the aim of achieving disease control and eventual elimination in Egypt.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt
Frank, C., Mohamed, M. K., Strickland, G. T., Lavanchy, D., Arthur, R. R., Magder, L. S., Khoby, T. E., Abdel-Wahab, Y., Ohn, E. S. A., Anwar, W., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(99)06527-7 · Cited by 1,131
Cited by
Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview
Rashed, W. M., Kandeil, M. A. M., Mahmoud, M. O., & Ezzat, S. (2020) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-020-0016-x · Cited by 283
Screening and Treatment Program to Eliminate Hepatitis C in Egypt
Waked, I., Esmat, G., Elsharkawy, A., El-Serafy, M., Abdel-Razek, W., Ghalab, R., Elshishiney, G., Salah, A., Abdel Megid, S., Kabil, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr1912628 · Cited by 282
Self-citationCurrent epidemiology in hepatocellular carcinoma
Konyn, P., Ahmed, A., & Kim, D. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1991792 · Cited by 280
Metadata
- Authors
- Gomaa, A., Allam, N., Elsharkawy, A., El Kassas, M., & Waked, I.
- Venue
- Hepatic Medicine: Evidence and Research
- Publisher
- Informa UK Limited
- Published
- 2017-05
- Volume
- Volume 9
- Pages
- 17-25
- ISSN
- 1179-1535 (ISSN-L)
- OpenAlex
- W2615797938
- Cited by
- 195
- References
- 2
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatitis C infection in Egypt: prevalence, impact and management strategies. https://app.cochat.ai/papers/10.2147/hmer.s113681
- The paper
- Gomaa, A., Allam, N., Elsharkawy, A., El Kassas, M., & Waked, I. (2017). Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepatic Medicine: Evidence and Research. https://doi.org/10.2147/hmer.s113681
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.